Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment.
chronic kidney disease
cognition
dialysis
glomerular filtration rate
vascular risk factors
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
24
05
2023
accepted:
12
06
2023
medline:
8
8
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Cognitive impairment is common in patients with chronic kidney disease (CKD), and early intervention may prevent the progression of this condition. Here, we review interventions for the complications of CKD (anemia, secondary hyperparathyroidism, metabolic acidosis, harmful effects of dialysis, the accumulation of uremic toxins) and for prevention of vascular events, interventions that may potentially be protective against cognitive impairment. Furthermore, we discuss nonpharmacological and pharmacological methods to prevent cognitive impairment and/or minimize the latter's impact on CKD patients' daily lives. A particular attention on kidney function assessment is suggested during work-up for cognitive impairment. Different approaches are promising to reduce cognitive burden in patients with CKD but the availabe dedicated data are scarce. There is a need for studies assessing the effect of interventions on the cognitive function of patients with CKD.
Sections du résumé
BACKGROUND
Cognitive impairment is common in patients with chronic kidney disease (CKD), and early intervention may prevent the progression of this condition.
METHODS
Here, we review interventions for the complications of CKD (anemia, secondary hyperparathyroidism, metabolic acidosis, harmful effects of dialysis, the accumulation of uremic toxins) and for prevention of vascular events, interventions that may potentially be protective against cognitive impairment. Furthermore, we discuss nonpharmacological and pharmacological methods to prevent cognitive impairment and/or minimize the latter's impact on CKD patients' daily lives.
RESULTS
A particular attention on kidney function assessment is suggested during work-up for cognitive impairment. Different approaches are promising to reduce cognitive burden in patients with CKD but the availabe dedicated data are scarce.
CONCLUSIONS
There is a need for studies assessing the effect of interventions on the cognitive function of patients with CKD.
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2899-2911Investigateurs
Alexandre Andrade
(A)
Maie Bachmann
(M)
Inga Bumblyte
(I)
Adrian Constantin Covic
(AC)
Nicole Endlich
(N)
Andreas Engvig
(A)
Denis Fouque
(D)
Casper Franssen
(C)
Sebastian Frische
(S)
Loreto Gesualdo
(L)
Dimitrios Goumenos
(D)
Laila-Yasmin Mani
(LY)
Hans-Peter Marti
(HP)
Christopher Mayer
(C)
Rikke Nielsen
(R)
Vesna Pešić
(V)
Merita Rroji Molla
(M)
Giorgos Sakkas
(G)
Kate Stevens
(K)
Evgueniy Vazelov
(E)
Davide Viggiano
(D)
Lefteris Zacharia
(L)
Ewout Hoorn
(E)
Andreja Figurek
(A)
Robert Unwin
(R)
Carsten Alexander Wagner
(CA)
Christoph Wanner
(C)
Dorothea Nitsch
(D)
Ivo Fridolin
(I)
Gaye Hafez
(G)
Maria José Soler Romeo
(MJ)
Bojan Batinić
(B)
Laura Carrasco
(L)
Ron Gansevoort
(R)
Gianvito Martino
(G)
Francesco Mattace Raso
(F)
Ionut Nistor
(I)
Alberto Ortiz
(A)
Daiva Rastenytė
(D)
Gabriel Stefan
(G)
Gioacchino Tedeschi
(G)
Boris Bikbov
(B)
Karl Hans Endlich
(KH)
Justina Kurganaite
(J)
Norberto Perico
(N)
Giuseppe Remuzzi
(G)
Francesco Trepiccione
(F)
Peter Blankestijn
(P)
Kai-Uwe Eckardt
(KU)
Danilo Fliser
(D)
Eugenio Gutiérrez-Jiménez
(E)
Maximilian Konig
(M)
Ivan Rychlik
(I)
Michela Deleidi
(M)
George Reusz
(G)
Michele Farisco
(M)
Norberto Perico
(N)
Pedro Henrique Imenez Silva
(PH)
Mickaël Bobot
(M)
Giovanna Capolongo
(G)
Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol. 2012;35(5):474-482. doi:10.1159/000338135
Berger I, Wu S, Masson P, et al. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med. 2016;14(1):206. doi:10.1186/s12916-016-0745-9
O'Lone E, Connors M, Masson P, et al. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67(6):925-935. doi:10.1053/j.ajkd.2015.12.028
Drew DA, Weiner DE, Sarnak MJ. Cognitive impairment in CKD: pathophysiology, management, and prevention. Am J Kidney Dis. 2019;74:782-790. doi:10.1053/j.ajkd.2019.05.017
McAdams-DeMarco MA, Daubresse M, Bae S, Gross AL, Carlson MC, Segev DL. Dementia, Alzheimer's disease, and mortality after hemodialysis initiation. Clin J Am Soc Nephrol. 2018;13(9):1339-1347. doi:10.2215/CJN.10150917
Torres RV, Elias MF, Seliger S, Davey A, Robbins MA. Risk for cognitive impairment across 22 measures of cognitive ability in early-stage chronic kidney disease. Nephrol Dial Transplant. 2017;32(2):299-306. doi:10.1093/ndt/gfw005
Sarnak MJ, Tighiouart H, Scott TM, et al. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013;80(5):471-480. doi:10.1212/WNL.0b013e31827f0f7f
Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008;15(2):123-132. doi:10.1053/j.ackd.2008.01.010
Lameire NH, Levin A, Kellum JA, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2021;100(3):516-526. doi:10.1016/j.kint.2021.06.028
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006
Gansevoort RT, Anders HJ, Cozzolino M, et al. What should European nephrology do with the new CKD-EPI equation? Nephrol Dial Transplant. 2022;38(1):1-6. doi:10.1093/ndt/gfac254
Pottel H, Björk J, Courbebaisse M, et al. Development and validation of a modified full age Spectrum creatinine-based equation to estimate glomerular filtration rate : a cross-sectional analysis of pooled data. Ann Intern Med. 2021;174(2):183-191. doi:10.7326/M20-4366
Delanaye P, Ebert N, Melsom T, et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: how to measure glomerular filtration rate with iohexol? Clin Kidney J. 2016;9(5):682-699. doi:10.1093/ckj/sfw070
Bikbov B, Soler MJ, Pešić V, et al. Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence? Nephrol Dial Transplant. 2021;37:gfab261. doi:10.1093/ndt/gfab261
Waas T, Schulz A, Lotz J, et al. Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. Sci Rep. 2021;11(1):10165. doi:10.1038/s41598-021-89442-7
Liu P, Quinn RR, Lam NN, et al. Accounting for age in the definition of chronic kidney disease. JAMA Intern Med. 2021;181(10):1359-1366. doi:10.1001/jamainternmed.2021.4813
Coresh J, Gansevoort RT, CKD Prognosis Consortium, Levin A, Jadoul M. KDIGO. Current CKD definition takes into account both relative and absolute risk. J Am Soc Nephrol. 2020;31(2):447-448. doi:10.1681/ASN.2019101049
Hommel K, Madsen M, Kamper AL. The importance of early referral for the treatment of chronic kidney disease: a Danish nationwide cohort study. BMC Nephrol. 2012;13:108. doi:10.1186/1471-2369-13-108
Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2021;99(1):34-47. doi:10.1016/j.kint.2020.10.012
Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-797. doi:10.1053/j.ajkd.2013.12.012
Kurella Tamura M, Xie D, Yaffe K, et al. Vascular risk factors and cognitive impairment in chronic kidney disease: the chronic renal insufficiency cohort (CRIC) study. Clin J Am Soc Nephrol. 2011;6(2):248-256. doi:10.2215/CJN.02660310
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. doi:10.1056/NEJMoa065485
Jarero-Basulto JJ, Rivera-Cervantes MC, Gasca-Martínez D, García-Sierra F, Gasca-Martínez Y, Beas-Zárate C. Current evidence on the protective effects of recombinant human erythropoietin and its molecular variants against pathological hallmarks of Alzheimer's disease. Pharmaceuticals (Basel). 2020;13(12):E424. doi:10.3390/ph13120424
Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346-1359. doi:10.1093/ndt/gft033
Iyalomhe O, Swierczek S, Enwerem N, et al. The role of hypoxia-inducible factor 1 in mild cognitive impairment. Cell Mol Neurobiol. 2017;37(6):969-977. doi:10.1007/s10571-016-0440-6
Agarwal R. Nonhematological benefits of iron. Am J Nephrol. 2007;27(6):565-571. doi:10.1159/000107927
Guedes M, Muenz D, Zee J, et al. Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrol Dial Transplant. 2021;36(9):1694-1703. doi:10.1093/ndt/gfab050
Jiang W, Hu CY, Li FL, Hua XG, Huang K, Zhang XJ. Elevated parathyroid hormone levels and cognitive function: a systematic review. Arch Gerontol Geriatr. 2020;87:103985. doi:10.1016/j.archger.2019.103985
Miglinas M, Cesniene U, Janusaite MM, Vinikovas A. Cerebrovascular disease and cognition in chronic kidney disease patients. Front Cardiovasc Med. 2020;7:96. doi:10.3389/fcvm.2020.00096
Mathur A, Ahn JB, Sutton W, et al. Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia. Nephrol Dial Transplant. 2022;37(11):2111-2118. doi:10.1093/ndt/gfac167
Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012;79(13):1397-1405. doi:10.1212/WNL.0b013e31826c197f
MacEwen C, Sutherland S, Daly J, Pugh C, Tarassenko L. Relationship between hypotension and cerebral ischemia during hemodialysis. J Am Soc Nephrol. 2017;28(8):2511-2520. doi:10.1681/ASN.2016060704
Polinder-Bos HA, García DV, Kuipers J, et al. Hemodialysis induces an acute decline in cerebral blood flow in elderly patients. J Am Soc Nephrol. 2018;29(4):1317-1325. doi:10.1681/ASN.2017101088
Findlay MD, Dawson J, Dickie DA, et al. Investigating the relationship between cerebral blood flow and cognitive function in hemodialysis patients. J Am Soc Nephrol. 2019;30(1):147-158. doi:10.1681/ASN.2018050462
Neumann D, Mau W, Wienke A, Girndt M. Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one-year course. Kidney Int. 2018;93(2):430-438. doi:10.1016/j.kint.2017.07.022
Eldehni MT, Odudu A, McIntyre CW. Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol. 2015;26(4):957-965. doi:10.1681/ASN.2013101086
Mustafa RA, Bdair F, Akl EA, et al. Effect of lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11(3):442-457. doi:10.2215/CJN.04580415
Dumaine CS, Ravani P, Parmar MK, Leung KCW, MacRae JM. In-center nocturnal hemodialysis improves health-related quality of life for patients with end-stage renal disease. J Nephrol. 2022;35(1):245-253. doi:10.1007/s40620-021-01066-2
Stringuetta Belik F, Silva OE, Rugolo V, et al. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? Nephrol Dial Transplant. 2021;37:gfab223. doi:10.1093/ndt/gfab223
Xu R, Pi HC, Xiong ZY, et al. Hyponatremia and cognitive impairment in patients treated with peritoneal dialysis. Clin J Am Soc Nephrol. 2015;10(10):1806-1813. doi:10.2215/CJN.02240215
Fan SS, Lin LF, Chen VCH, et al. Effects of lower past-year serum sodium and hyponatremia on depression symptoms and cognitive impairments in patients with hemodialysis. Ther Apher Dial. 2020;24(2):169-177. doi:10.1111/1744-9987.13395
Viggiano D, Wagner CA, Blankestijn PJ, et al. Mild cognitive impairment and kidney disease: clinical aspects. Nephrol Dial Transplant. 2019;35:10-17. doi:10.1093/ndt/gfz051
Imenez Silva PH, Unwin R, Hoorn EJ, et al. Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. Nephrol Dial Transplant. 2021;37(Suppl 2):ii4-ii12. doi:10.1093/ndt/gfab216
Pépin M, Ferreira AC, Arici M, et al. Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. Nephrol Dial Transplant. 2021;37:ii23-ii32. doi:10.1093/ndt/gfab262
Kang EW, Abdel-Kader K, Yabes J, Glover K, Unruh M. Association of sleep-disordered breathing with cognitive dysfunction in CKD stages 4-5. Am J Kidney Dis. 2012;60(6):949-958. doi:10.1053/j.ajkd.2012.08.033
Nicholl DDM, Ahmed SB, Loewen AHS, et al. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest. 2012;141(6):1422-1430. doi:10.1378/chest.11-1809
Viggiano D, Wagner CA, Martino G, et al. Mechanisms of cognitive dysfunction in CKD. Nat Rev Nephrol. 2020;16(8):452-469. doi:10.1038/s41581-020-0266-9
Natale P, Ruospo M, Saglimbene VM, Palmer SC, Strippoli GF. Interventions for improving sleep quality in people with chronic kidney disease. Cochrane Database Syst Rev. 2019;5(5):CD012625. doi:10.1002/14651858.CD012625.pub2
Gregg LP, Hedayati SS. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Curr Opin Nephrol Hypertens. 2020;29(5):457-464. doi:10.1097/MNH.0000000000000629
Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956-965. doi:10.1016/j.jacc.2010.02.068
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi:10.1136/bmj.324.7329.71
Laville SM, Lambert O, Hamroun A, et al. Consequences of oral antithrombotic use in patients with chronic kidney disease. Clin Transl Sci. 2021;14(6):2242-2253. doi:10.1111/cts.13084
Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in reducing events in the elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;99(2):466-474. doi:10.1016/j.kint.2020.08.011
Tanios BY, Itani HS, Zimmerman DL. Clopidogrel use in end-stage kidney disease. Semin Dial. 2015;28(3):276-281. doi:10.1111/sdi.12338
Kelly DM, Rothwell PM. Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. Kidney Int. 2020;97(2):266-278. doi:10.1016/j.kint.2019.09.024
Mann JFE, Joseph P, Gao P, et al. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2023;103(2):403-410. doi:10.1016/j.kint.2022.09.023
Wong CX, Odutayo A, Emdin CA, Kinnear NJ, Sun MT. Meta-analysis of anticoagulation use, stroke, thromboembolism, bleeding, and mortality in patients with atrial fibrillation on dialysis. Am J Cardiol. 2016;117(12):1934-1941. doi:10.1016/j.amjcard.2016.03.042
Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of Oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2019;171(3):181-189. doi:10.7326/M19-0087
Liabeuf S, Laville SM, Bieber B, et al. Prescription of direct Oral anticoagulants to patients with moderate-to-advanced CKD: too little or just right? Kidney Int Rep. 2021;6(9):2496-2500. doi:10.1016/j.ekir.2021.06.004
Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with Apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519-1529. doi:10.1161/CIRCULATIONAHA.118.035418
Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban versus warfarin in patients with Nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. 2019;132(9):1078-1083. doi:10.1016/j.amjmed.2019.04.013
Mavrakanas TA, Garlo K, Charytan DM. Apixaban versus No anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol. 2020;15(8):1146-1154. doi:10.2215/CJN.11650919
Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80(6):572-586. doi:10.1038/ki.2011.223
Ungvari Z, Toth P, Tarantini S, et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021;17(10):639-654. doi:10.1038/s41581-021-00430-6
Johansen KL, Garimella PS, Hicks CW, et al. Central and peripheral arterial diseases in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2021;100(1):35-48. doi:10.1016/j.kint.2021.04.029
Chen YH, Chen YY, Fang YW, Tsai MH. Protective effects of angiotensin receptor blockers on the incidence of dementia in patients with chronic kidney disease: a population-based Nationwide study. J Clin Med. 2021;10(21):5175. doi:10.3390/jcm10215175
Fournier A, Oprisiu-Fournier R, Serot JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413-1431. doi:10.1586/ern.09.89
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013;9:CD004289. doi:10.1002/14651858.CD004289.pub5
Wanner C, Tonelli M. Kidney disease: improving global outcomes lipid guideline development work group members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303-1309. doi:10.1038/ki.2014.31
Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF. Statins, cognition, and dementia-systematic review and methodological commentary. Nat Rev Neurol. 2015;11(4):220-229. doi:10.1038/nrneurol.2015.35
Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-1643. doi:10.1016/S0140-6736(20)32332-1
Ariton DM, Jiménez-Balado J, Maisterra O, Pujadas F, Soler MJ, Delgado P. Diabetes, albuminuria and the kidney-brain Axis. J Clin Med. 2021;10(11):2364. doi:10.3390/jcm10112364
Tsai WH, Chuang SM, Liu SC, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep. 2021;11(1):15364. doi:10.1038/s41598-021-94945-4
Lu CH, Yang CY, Li CY, Hsieh CY, Ou HT. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia. 2018;61(3):562-573. doi:10.1007/s00125-017-4499-5
Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-848. doi:10.1056/NEJMoa1616011
Kelly ME, Loughrey D, Lawlor BA, Robertson IH, Walsh C, Brennan S. The impact of exercise on the cognitive functioning of healthy older adults: a systematic review and meta-analysis. Ageing Res Rev. 2014;16:12-31. doi:10.1016/j.arr.2014.05.002
Pentikäinen H, Savonen K, Ngandu T, et al. Cardiorespiratory fitness and cognition: longitudinal associations in the FINGER study. J Alzheimers Dis. 2019;68(3):961-968. doi:10.3233/JAD-180897
Cai H, Li G, Hua S, Liu Y, Chen L. Effect of exercise on cognitive function in chronic disease patients: a meta-analysis and systematic review of randomized controlled trials. Clin Interv Aging. 2017;12:773-783. doi:10.2147/CIA.S135700
Vanderbeken I, Kerckhofs E. A systematic review of the effect of physical exercise on cognition in stroke and traumatic brain injury patients. NeuroRehabilitation. 2017;40(1):33-48. doi:10.3233/NRE-161388
Martins CTB, Ramos GSM, Guaraldo SA, Uezima CBB, Martins JPLB, Ribeiro JE. Comparison of cognitive function between patients on chronic hemodialysis who carry out assisted physical activity and inactive ones. J Bras Nefrol. 2011;33(1):27-30.
Stringuetta Belik F, Silva OE, Rugolo V, et al. Influence of intradialytic aerobic training in cerebral blood flow and cognitive function in patients with chronic kidney disease: a pilot randomized controlled trial. Nephron. 2018;140(1):9-17. doi:10.1159/000490005
McAdams-DeMarco MA, Konel J, Warsame F, et al. Intradialytic cognitive and exercise training may preserve cognitive function. Kidney Int Rep. 2018;3(1):81-88. doi:10.1016/j.ekir.2017.08.006
Manfredini F, Mallamaci F, D'Arrigo G, et al. Exercise in patients on dialysis: a multicenter, randomized clinical trial. J Am Soc Nephrol. 2017;28(4):1259-1268. doi:10.1681/ASN.2016030378
Uchiyama K, Washida N, Morimoto K, et al. Home-based aerobic exercise and resistance training in peritoneal dialysis patients: a randomized controlled trial. Sci Rep. 2019;9(1):2632. doi:10.1038/s41598-019-39074-9
Otobe Y, Yamada M, Hiraki K, et al. Physical exercise improves cognitive function in older adults with stage 3-4 chronic kidney disease: a randomized controlled trial. Am J Nephrol. 2021;52(12):929-939. doi:10.1159/000520230
Cicerone KD, Goldin Y, Ganci K, et al. Evidence-based cognitive rehabilitation: systematic review of the literature from 2009 through 2014. Arch Phys Med Rehabil. 2019;100(8):1515-1533. doi:10.1016/j.apmr.2019.02.011
Chandler MJ, Parks AC, Marsiske M, Rotblatt LJ, Smith GE. Everyday impact of cognitive interventions in mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev. 2016;26(3):225-251. doi:10.1007/s11065-016-9330-4
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5
McAdams-DeMarco MA, Chu NM, Steckel M, et al. Interventions made to preserve cognitive function trial (IMPCT) study protocol: a multi-dialysis center 2x2 factorial randomized controlled trial of intradialytic cognitive and exercise training to preserve cognitive function. BMC Nephrol. 2020;21(1):383. doi:10.1186/s12882-020-02041-y
Chauveau P, Aparicio M, Bellizzi V, et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease. Nephrol Dial Transplant. 2018;33(5):725-735. doi:10.1093/ndt/gfx085
Lauriola M, Farré R, Evenepoel P, Overbeek SA, Meijers B. Food-derived uremic toxins in chronic kidney disease. Toxins (Basel). 2023;15(2):116. doi:10.3390/toxins15020116
Liabeuf S, Laville M. Drug prescription in patients with chronic kidney disease: a true challenge. Nephrol Dial Transplant. 2021;36(3):385-386. doi:10.1093/ndt/gfaa164
Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69(7):1485-1496. doi:10.1007/s00228-013-1499-3
Broder JC, Ryan J, Shah RC, et al. Anticholinergic medication burden and cognitive function in participants of the ASPREE study. Pharmacotherapy. 2022;42(2):134-144. doi:10.1002/phar.2652
Dou KX, Tan MS, Tan CC, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126. doi:10.1186/s13195-018-0457-9
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021;2:CD013306. doi:10.1002/14651858.CD013306.pub2
Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J. 2013;34(33):2585-2591. doi:10.1093/eurheartj/eht182
Morris R, Luboff H, Jose RP, et al. Bradycardia due to donepezil in adults: systematic analysis of FDA adverse event reporting system. J Alzheimers Dis. 2021;81(1):297-307. doi:10.3233/JAD-201551
Kambayashi R, Goto A, Hagiwara-Nagasawa M, et al. Analysis of clinically-reported, memantine-induced cardiovascular adverse responses using the halothane-anesthetized dogs: reverse translational study. J Pharmacol Sci. 2022;148(4):343-350. doi:10.1016/j.jphs.2022.01.011
Hilderman M, Bruchfeld A. The cholinergic anti-inflammatory pathway in chronic kidney disease-review and vagus nerve stimulation clinical pilot study. Nephrol Dial Transplant. 2020;35(11):1840-1852. doi:10.1093/ndt/gfaa200
Decourt B, D'Souza GX, Shi J, Ritter A, Suazo J, Sabbagh MN. The cause of Alzheimer's disease: the theory of multipathology convergence to chronic neuronal stress. Aging Dis. 2022;13(1):37-60. doi:10.14336/AD.2021.0529
EMA. Exelon. European Medicines Agency. 2018 Accessed July 13, 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/exelon
EMA. Ebixa. European Medicines Agency. 2018 Accessed July 13, 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/ebixa
Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013;52(4):225-241. doi:10.1007/s40262-013-0038-9